Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | OSBP | P22059 | 1/20 | 0.67 |
| ▸ | RORC | P51449 | 1/20 | 0.67 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.67 |
| ▸ | POLA1 | P09884 | 1/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.61 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637585 | 1.00 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963051 | 0.92 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27963054 | 0.92 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL27975861 | 0.92 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2638134 | 0.92 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL6060845 | 0.92 | USP2 (0.68) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22194040 | 0.91 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22194041 | 0.91 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8426935 | 0.91 | USP2 (0.67) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18631920 | 0.90 | USP2 (0.63) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024144348-A1 | VACCINE COMPOSITION COMPRISING IONIC COMPLEX OF CATIONIC MOLECULAR TRANSPORTER AND MRNA | 주식회사 바이오파마 | 2024-07-04 | — | — | WO | claimed |
| CN-118201605-A | POEGMA-based lipid nanoparticles | 杜克大学 | 2024-06-14 | — | — | CN | claimed |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | EYEGENE INC. (KR) | 2024-05-23 | — | — | US | claimed |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | EYEGENE INC. (KR) | 2024-05-09 | — | — | US | claimed |
| EP-4356933-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | Eyegene, Inc. (KR) | 2024-04-24 | — | — | EP | claimed |
| WO-2024054020-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | 아이진 주식회사 | 2024-03-14 | — | — | WO | claimed |
| EP-4306132-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPARATION METHOD THEREFOR | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| EP-4306126-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| CN-116940376-A | Vaccine composition for preventing SARS-COV-2 | 艾金株式会社 | 2023-10-24 | — | — | CN | claimed |
| CN-115957382-A | Medical instrument for interventional therapy | 凯诺威医疗科技(武汉)有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-11406742-B2 | Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs | M.A. Med Alliance SA (CH) | 2022-08-09 | — | — | US | claimed |
| US-20220054370-A1 | MULTILAYERED CATIONIC LIPOSOME FOR ENHANCING SKIN ABSORPTION AND PREPARATION METHOD THEREFOR | COSMAX, INC. (KR) | 2022-02-24 | — | — | US | claimed |
| EP-2839015-B1 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS | UNIV RAMOT (IL) | 2020-04-29 | — | — | EP | claimed |
| CN-110179753-A | Nano medication delivery system and its preparation and the application of a kind of targeting brain tumor and its tumor stem cell | 上海市同仁医院 | 2019-08-30 | — | — | CN | claimed |
| CN-102989007-B | The extensive method preparing injection Midkine antisense oligonucleotide nano liposome | CENTRAL HOSPITAL, HUZHOU CITY (CN) | 2015-12-16 | — | — | CN | claimed |
| CN-104906567-A | Application of ligand-mediated dendritic cell targeting Texosomes bionic body as tumor vaccine | UNIV SHENYANG PHARMACEUTICAL | 2015-09-16 | — | — | CN | claimed |
| EP-2839015-A1 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS | Ramot at Tel-Aviv University Ltd. (IL) | 2015-02-25 | — | — | EP | claimed |
| CN-104043133-A | Gene medicine for targeted inhibition of lung cancer cells and preparation method thereof | GUANGZHOU JKTT CO LTD | 2014-09-17 | — | — | CN | claimed |
| CN-104043134-A | Nano-liposome as well as preparation method and application thereof | GUANGZHOU JKTT CO LTD | 2014-09-17 | — | — | CN | claimed |
| WO-2013156989-A1 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES FOR THE DELIVERY OF NUCLEIC ACIDS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | ACE2, SARS1, RBM22 | USP2 158/4885CYP46A1 1357/4885LMNA 2735/4885 |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | RTCB, RRP1B, PRPF6 | USP2 2649/4885CYP46A1 733/4885LMNA 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.